4.6
2.2
| Citation: |
Song Jun, Zhang Jifeng, Xu Jie, Garcia-Barrio Minerva, Chen Y. Eugene, Yang Dongshan. Genome engineering technologies in rabbits[J]. The Journal of Biomedical Research, 2021, 35(2): 135-147. DOI: 10.7555/JBR.34.20190133
|
Rabbit (Oryctolagus cuniculus) is a classic research animal model and is increasingly becoming a translational model of choice, serving to bridge the gap between rodent models and larger animal models[1–5]. Similar to rodents, the rabbit has several advantages to be a classic research animal model, such as relatively inexpensive housing, facile breeding, short gestation (28–32 days for New Zealand white rabbit, NZW) and large litter size (4–10 kits per litter for NZW). Additionally, rabbits share characteristics with larger animals that are phylogenetically, physiologically, and anatomically closer to humans[6–7]. As early as the nineteenth century, rabbits were used to develop the rabies vaccine by Louis Pasteur[8] and also played a vital role in the discovery of Mycobacterium tuberculosis[9]. The rabbit model has provided tremendous breakthroughs and insights into understanding the molecular and cellular mechanisms of atherosclerosis, including the discoveries of low-density lipoprotein receptor deficiency as a cause for human familial hypercholesterolemia[10] and statin, the most potent lipid-lowering drug[10-11] which is prescribed annually for more than 30 million hyperlipidemic patients worldwide.
Both embryo transfer and in vitro fertilization, two of the basic techniques for transgenic animal technology, were developed first in rabbits[12–13]. A transgenic animal carries an exogenous DNA cassette, and the foreign DNA cassette that could be transmitted through the germ line. Transgenic animals represent unique models that are custom tailored to address specific biological questions. They therefore provide a very powerful tool for dissecting complex biological processes and systems and identifying specific gene functions. Since the first transgenic rabbit produced by Hammer and his colleagues[14], transgenic rabbit models have been generated by different laboratories worldwide for different research purposes: (a) human disease models, like infectious disease[4], cardiovascular disease[3,5], ophthalmic disease[15], respiratory disease[16], and nervous system disease[17]; (b) production of human proteins as mammary gland bioreactors[18]; (c) toxicity tests[17] and (d) antibody production[18]. Most of these models were produced by microinjection of DNA into fertilized eggs which results in random integrations of the exogenous DNA into the rabbit genome. This can lead to multi-copy integration, unpredictable expression of the transgene and inadvertent disruption of neighboring genes or the gene at the insertion site[19]. To solve this problem, gene targeting technology was developed in mice, in which foreign DNA could be targeted and integrated into a specific locus by homologous recombination (HR) in pluripotent stem cells (PSCs) followed by chimera production. Gene targeting allowed precise manipulation of the genome to avoid the problems caused by random insertion. More importantly, it allowed scientists to study human genetic diseases by removing or adding, specific mutations in the animal genome in order to establish the roles of individual genes in healthy and diseased animals. In large animals such as pigs, sheep and cattle, in which the germline competent PSCs are not available, gene targeting could be achieved by HR in cultured somatic cells, followed by somatic cell nuclear transfer (SCNT) (Fig. 1). However, due to lack of germline competent PSC lines and the extreme difficulty of SCNT in rabbits, the gene targeting technology in rabbits lagged behind that in rodents as well as in pigs.
While the first success in rabbit pronuclear microinjection was achieved within 5 years from the first in mouse, it took 24 more years to achieve gene targeting in rabbits after it was first reported in mouse (Fig. 2). Due to the technical lagging, the development and application of genetically engineered rabbit models are much limited. Recently, with the advent of gene editing nucleases, including, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats/CRISPR-associated protein-9 (CRISPR/Cas9), it is now possible to modify the rabbit genome precisely and efficiently. In this review, we summarize the brief history of transgenic rabbit technology and the progress of engineered endonuclease-mediated precise genome editing in rabbits.
There are mainly three traditional methods for generation of transgenic animals, including DNA microinjection-mediated transgenesis, PSCs-mediated transgenesis and SCNT-mediated transgenesis (Fig. 1). Other methods of transgenic animal production like sperm-mediated gene transfer[42], and viral-mediated gene transfer[43], have also been reported, but these methods have considerable problems with reproducibility and transgene rearrangement as well as low efficiency[43–45].
In the early 1980s, the technology for generation of transgenic mice was reported by several groups[21–25], which described the direct microinjection of the DNA fragment of interest into the zygotic pronuclei. It was the first effective technique to produce a transgenic mammal, subsequently widely applied to generate transgenic animals in a wide variety of species in the following decades. In 1985, the first transgenic rabbit was produced by Robet E. Hammer and colleagues[14]. They injected the pronuclear stage embryos with a fusion gene consisting of the human growth hormone driven by the mouse metallothionein-I promoter (MT-hGH). The efficiency of MT-hGH integration into the rabbit genome reached 12% and the foreign gene was inherited through germline transmission. Afterwards, due to the advantage of being straightforward and reliable, the DNA microinjection method has been used to establish numerous transgenic rabbit models for research in cardiovascular disease, infectious disease, bioreactors and so on[2,18], and the method remained to be the most reliable and commonest means of producing transgenic rabbits until recently. Despite numerous attempts to improve the efficiency of microinjection-mediated transgenic animal production[46], none of these efforts could solve one of the most prominent disadvantages of the pronuclear injection mediated transgenesis, that is, random integration. Recently, with the development of transposon mediated gene transfer technology, pronuclear microinjection of Sleeping Beauty transposons achieved promising results in rabbits, with single copy, stable and reproducible gene expression, though the integration site is still uncontrollable[47–48].
Gene targeting is the process of creating designed genomic modifications at a specific sequence in a genome. Such modifications could be deletion, insertion or replacement of endogenous sequence. PSCs-mediated gene targeting in mice has revolutionized the study of developmental biology and human medicine. The PSCs can be derived from preimplantation embryos (embryonic stem cells, ES cells) or reprogrammed from differentiated cells (induced pluripotent stem cells, iPS cells). The PSCs possess robust proliferative ability and pluripotency which makes the PSCs bear capability to differentiate into various cell types, including germ cells. To precisely modify the endogenous gene or deliver a foreign gene fragment into the target site, the PSCs in culture were transfected to introduce the desired modification via HR. After screening, the PSCs with the desired modifications could be injected into a blastocyst stage embryo, and the gene modified PSCs will differentiate and incorporate into the host germline. Then, following breeding could thus generate the gene targeted animal model (Fig. 1). In 1981, two groups of scientists successfully isolated and cultured ES cells from the mouse[49–50]. These cells were shown to be able to differentiate into multiple cell types including germline and could generate transgenic offspring when the genetically altered ES cells were injected into mouse blastocysts[51–52]. Since HR events in ES cells could be screened and enriched in a petri dish, ES cells have subsequently been widely used as vehicles to produce gene-targeted mouse models[53]. More recently, with the development of iPS technology[54–55], live pups were generated using pluripotent iPS cells through tetraploid complementation in different independent laboratories[56–58], indicating iPS cells could also be used for generating gene targeted animal models. Using PSCs-mediated gene targeting, genetically modified mice have been produced to perform gain- and loss-of-function genetic studies, to follow gene expression or determine cell lineage, and/or to control the effects of mutations spatially and temporally[59]. This versatile technology has rendered the mouse a powerful and indispensable experimental model in fundamental basic and medical research and thus a dominant animal species in the biomedical sciences.
Unfortunately, PSCs technology in rabbits has lagged behind considerably compared to that in mice. Although a number of groups[60–66] have reported the successful establishment of rabbit ES cells and iPS cells, which exhibit the characteristic features of primed pluripotency similar to those of human pluripotent stem cells, and some cell lines can be passaged for at least 50 times or more than 1 year, almost all of the established cell lines have low or no chimeric competency, and no germline transmission has been reported yet. Interested readers can refer to a comprehensive review of rabbit PSCs[67].
Since the first cloned sheep, Dolly, was reported in 1996[26], the technique of SCNT combined with somatic cell gene modification provided an alternative for gene targeting in mammals, especially in large animal species that do not have germline competent PCS lines available[68–70]. In this approach, the genetic manipulation can be performed in cultured somatic cells, and then single cell clones with the expected modification are screened and transferred into enucleated oocytes. The reconstituted embryos are then transferred into the oviducts of surrogate females for animal production (Fig. 1). All cloned offspring would have the same genotype as the donor cell.
The rabbit is one of the earliest mammals used for nuclear transfer studies. In 1988, the first cloned rabbit generated with embryonic blastomere nuclear transfer was reported[71]. In 2002, the first somatic cell cloned rabbit was successfully produced by Renard's group in France using freshly collected cumulus cells as nuclear donor rather than cultured somatic cells[28]. It turned out that the SCNT in rabbits is extremely difficult with high miscarriage rates and perinatal mortality[72]. In 2006, Li et al produced cloned rabbits from cultured adult fibroblasts[73], which enabled genetic manipulation and screening before nuclear transfer. After that, transgenic rabbits expressing green fluorescent protein were cloned using in vitro transfected adult fibroblasts[29] and mesenchymal stem cells[66,74]. In 2015, the first SCNT-mediated gene knockout (KO) rabbit was finally reported[75] using recombinant adeno-associated virus-mediated HR and SCNT. In the study, 18 cloned kits were born from 38 recipients with 784 embryos transferred, and only 5 cloned kits were alive at weaning. In addition, the authors noted that delivery of the HR vectors to rabbit fibroblasts is the major barrier, and no targeted cellular clones were identified using electroporation- and liposome-mediated DNA delivery. The limited somatic cell proliferation and low frequency of HR in adult fibroblasts and the extremely low efficiency of SCNT in rabbits limited the application of SCNT in rabbit gene targeting.
Recently ZFN, TALEN, and CRISPR/Cas9 have emerged as powerful programmable tools for genome editing[76–77]. These engineered endonucleases are efficient in generating double-strand breaks (DSB) in the specific genomic loci that can be repaired either by error-prone, non-homologous end joining (NHEJ) leading to frameshifts which may result in a functional KO of the target gene or by homology directed repair (HDR) to integrate a mutation or a DNA insert at a specific locus. Thanks to the very high rates of targeted DSB, gene targeted animals can be now readily derived by direct injection of the engineered endonucleases together with or without donor DNA into pronuclear stage embryos, bypassing the need for germline competent PSCs or highly efficient SCNT[37,78].
The prototype enzymes for demonstrating DSB stimulation of gene targeting were meganucleases, I-SceI and HO, both of which recognize long DNA target (18 bp for I-SceI, 24 bp for HO)[79]. While they provided very useful information on the efficiency and mechanisms of DSB repair, they were limited in their utility because it is difficult to alter their recognition sequences, rendering them non-programmable. ZFNs were the first generation of the programmable genome editing nucleases. Kim et al, in 1996[80], first designed and cleaved target DNA in vitro using a ZFN pair that consisted of two different zinc finger proteins (DNA-binding domains) each linked with a Fok I endonuclease domain. Zinc finger domains can be engineered to target specific DNA sequences and this enables ZFNs to target unique sequences within complex genomes. During the process of DNA-protein recognition, zinc finger proteins recognize the 18 bp target sequence through 6 tandem fingers, each of which primarily recognizes 3 bp of DNA. Once both zinc finger proteins bind to target sites that lie in inverted orientation, the two Fok I endonuclease domains form a functional dimer to cleave the target DNA sequence. Then, the DNA repair pathway is subsequently triggered and the mutation is generated.
ZFNs were first applied to in vivo genome editing in the fruit fly[27], and later widely used to modify target genes in other organisms[30,81–84]. In rabbit, ZFNs were first engineered to KO the immunoglobin gene through pronuclear stage embryo microinjection with ZFN mRNA[31]. The phenotypes of immunoglobin locus KO were confirmed by serum IgM and IgG deficiency and lack of IgM+ and IgG+ B lymphocytes. The study also found that targeted sequence replacement (knock-in, KI) occurred in the target site with the presence of a linear DNA donor. Our lab and others also employed ZFNs to generate rabbit models for lipid metabolism[85] and atherosclerosis[86–88] studies. However, the expensive Zinc Finger library, the laborious engineering and assembly process of ZFNs and the complexity of ZF-DNA recognition restrict its practical application in genome editing.
TALENs are considered an upgraded version of programmable nucleases that are similar to ZFNs but much simpler to design and assemble. The DNA binding domain in TALENs was derived from Xanthomonas spp. bacteria[89–90]. While TALENs utilize the same Fok I endonuclease domain as ZFNs, its DNA binding domain contains a repeated highly conserved 33–34 amino acid sequence with Repeat Variable Diresidue (RVD) at 12th and 13th amino acids, which recognizes specific nucleotides, for example, NN for guanine, NI for adenine, HD for cytosine and NG for thymine. This straightforward relationship between amino acid sequence and DNA recognition has allowed for easier engineering of sequence specific binding domains than with ZFNs[91–92].
Since the TALEN domains allow for a more predictable, modular creation of binding domains, they gained immediate popularity after ZFNs. To date, TALENs have already been utilized to introduce various gene modifications in a large number of organisms and cultured cell lines. In rabbits, this technique was first used to target Rag1 and Rag2 genes to generate immunodeficent rabbits by microinjection of TALENs mRNA into single-cell stage embryos[36]. In this study, extremely high efficiency of KO, in both in vitro cultured embryos and in offspring, were achieved in rabbits. The gene targeted rabbits show typical pathological phenotypes, such as absence of the thymus and consequent deficiency of T and B lymphocytes, which are consistent with those of immunodeficient patients. Like ZFNs, TALENs rely on protein-DNA recognition and thus need to be designed and assembled according to each target, which is laborious and time consuming.
The CRISPR/Cas9 technology is the most recent version of the programmable genome editing nucleases, and is even more rapid and modular than the TALEN platform. Cas9 is an endonuclease enzyme playing a protective role against foreign nucleic acids in the CRISPR adaptive immune system in bacteria. The feature of bacterial CRISPR immune system is that genetic materials taken up from previous invasive elements are expressed in crRNA, which could direct the Cas9 endonuclease to cut foreign DNA elements containing the same sequence[33–34]. Therefore, to modify the sequence of the eukaryotic genome, the CRISPR/Cas9 system has been remolded from bacterial immune system to genome editing tool, using a designed guide RNA to target Cas9 nuclease to a specific DNA sequence[93]. Binding of Cas9 nuclease on a specific protospacer adjacent motif (PAM) sequence on the genome (NGG for spCas9) will unwind the adjacent sequence, allowing the RNA: DNA pairing, which activates the nuclease domains in Cas9 to cut DNA double strands. While ZFNs and TALENs rely on protein-DNA recognition, which is less predictable for design and more labor and time consuming for assembly because of the difficulties of protein construction, synthesis, purification and validation, the CRISPR/Cas9 system relies on the RNA–DNA recognition, which is much simpler and more predictable.
In 2014, our lab was first to report CRISPR/Cas9 system mediated gene targeting in rabbits[37] (Fig. 3). In this study, we found that the efficiency of KO introduced by CRISPR/Cas9 was up to 100% in rabbit embryos and 84% in rabbit kits, and no off-target effects were detected at bioinformatically predicted off-target sites in the offspring. We refer the interested readers to detailed protocols for this technology in rabbits[94]. In the years since, more than a dozen of genetically modified rabbits were reported through CRISPR/Cas9 system (Table 1), among which, human disease models are dominant, including models for hyperlipidemia[87], Marfan syndrome[96], muscular dystrophy[97–98], immunodeficiency[114–115], congenital cataracts[99–100], Wilson disease[111], tyrosinemia type 1[95] and premature aging syndrome[107]. Using CRISPR/Cas9 technology, most of the complex genetic manipulations, including point mutation, large fragment replacement, large deletion, conditional KO, etc., that were previously only achievable in rodents could now be fulfilled in rabbits. For example, two groups efficiently introduced disease causing point mutations in rabbits using CRISPR/Cas9 system combined with single-strand oligodeoxyribonucleotide (ssODNs) as donor to establish rabbit model of oculocutaneous albinism and Wilson disease, respectively[111–112]. To find a safe harbor locus in rabbit genome for the KI of transgenes and its stable expression, we identified and characterized the rabbit Rosa26 locus (rbRosa26), and achieved highly efficient KI rates and constitutive, ubiquitous foreign gene expression[118]. To improve large fragment KI efficiency, we found that an HDR enhancer, RS-1, is beneficial for TALEN and CRISPR/Cas9 mediated large fragment KI, with approximately 2 –4 fold increase at two rabbit specific loci[119]. To achieve large fragment deletion, dual guide RNAs were employed to target the rabbit genome, and up to 105 kb fragment deletion was achieved in 10% and 17.67% of rabbit embryos and live pups, respectively[113].
| Nucleases | Genes | Modification | Components | Injected site | Application | Reference |
| ZFN | IGM | KO/KI | ZFN mRNA | Cytoplasm | Immunology | |
| APOCIII | KO | ZFN mRNA | Cytoplasm | Lipid metabolism and atherosclerosis | [85] | |
| APOE | KO | ZFN mRNA | Pronuclear | Lipid metabolism and atherosclerosis | [86] | |
| CETP | KO | ZFN mRNA | Cytoplasm | Lipid metabolism and atherosclerosis | [88] | |
| TALENs | RAG1 | KO | TALEN mRNA | Cytoplasm | Immunodeficiency | [36] |
| RAG2 | KO | |||||
| FAH | KO | TALEN mRNA | Cytoplasm | Hereditary tyrosinemia type 1 | [95] | |
| CRISPR/ Cas9 | FBN1 | KO | Cas9 mRNA, sgRNA | Cytoplasm | Marfanoid-progeroid- lipodystrophy syndrome | [96] |
| DMD | KO | Cas9 mRNA, sgRNA | Cytoplasm | Duchenne muscular dystrophy | [97] | |
| ANO5 | KO | Cas9 mRNA, sgRNA | Cytoplasm | Muscular dystrophy | [98] | |
| aA-Crystallin | KO | Cas9 mRNA, dual sgRNA | Cytoplasm | Congenital cataracts | [99] | |
| GJA8 | KO | Cas9 mRNA, dual sgRNA | Cytoplasm | Congenital cataracts | [100] | |
| APOE | KO | Cas9 mRNA, sgRNA | Cytoplasm | Lipid metabolism and atherosclerosis | [37] | |
| LDLR | KO | |||||
| CD36 | KO | |||||
| RYR2 | KO | Cas9 mRNA, sgRNA | Cytoplasm | Heart arrhythmia. | ||
| LDLR | KO | Cas9 mRNA, sgRNA | Cytoplasm | Lipid metabolism and atherosclerosis | [101] | |
| MSTN | KO | Cas9 mRNA, sgRNA | Cytoplasm | Muscle hypertrophy | [102-103] | |
| SRY | KO | Cas9 mRNA, sgRNA | Cytoplasm | Sex reversal syndromes and hermaphroditism syndromes | [104-105] | |
| PHEX | KO | Cas9 mRNA, dual sgRNA | Cytoplasm | X-linked hypophosphatemia | [106] | |
| LMNA | KO | Cas9 mRNA, sgRNA | Cytoplasm | Premature aging syndrome | [107] | |
| WRN | KO | Cpf1 mRNA, sgRNA | Cytoplasm | Werner syndrome | [108] | |
| TYR | KO | Circular plasmid | Pronuclear | Coat color | [109] | |
| TYR | KO | Cas9 mRNA, dual sgRNAs | Cytoplasm | Coat color | [110] | |
| ATP7B | Precision point mutation | Cas9 mRNA, 2sgRNA, ssODN | Cytoplasm | Wilson Disease | [111] | |
| TYR | Precision point mutation | Cas9 mRNA, sgRNA, ssODN | Cytoplasm | Coat color | [112] | |
| TYR | KO, large fragment deletion | Cas9 mRNA, dual sgRNAs | Cytoplasm | Coat color | [113] | |
| FOXN1 | Multiplex gene KO | Cas9 mRNA, sgRNA | Cytoplasm | Immunodeficiency | [114-115] | |
| PRKDC | ||||||
| RAG1 | Multiplex gene KO | Cas9 mRNA, sgRNA | Cytoplasm | Immunodeficiency | [114-116] | |
| RAG2 | ||||||
| IL2RG | ||||||
| TIKI1 | Multiplex gene KO | Cas9 mRNA, sgRNA | Cytoplasm | Head development | [28] | |
| ALB | Serum albumin | |||||
| FUT1 | Multiplex gene KO using a single sgRNA | Cas9 mRNA, sgRNA | Cytoplasm | Fucosyltransferases enzymes activity | [117] | |
| FUT2 | ||||||
| SEC1 | ||||||
| ROSA 26 | KI | Cas9 mRNA, sgRNA, dsDNA | Cytoplasm | Safe harbor gene | [118-119] | |
| APOA1 | Cytoplasm | Lipid metabolism and atherosclerosis | ||||
| Base editor | MSTN | Base editing | BE3 mRNA | Cytoplasm | Muscle hypertrophy | [41] |
| LMNA | Hutchinson−Gilford progeria syndrome | |||||
| TYR | Coat color | |||||
| DMD | Base editing | ABE7.10 mRNA | Cytoplasm | Duchenne muscular dystrophy | ||
| KO: knock-out; KI: knock-in. | ||||||
DownLoad:
CSV
By attaching functional domains to nuclease inactive Cas9, it is possible to target many functionalities to a specific genomic location. Recently, a series of targeted base editing technologies were developed by fusion of cytidine deaminase or adenine deaminase with nuclease inactive Cas9[39,120–122]. Under the guide and binding of inactive Cas9 or Cas9 nickase, the deaminase converts target C:G-to-T:A or A:T-to-G:C, which holds great promise to treat various genetic diseases caused by point mutations. In rabbits[41], the cytidine base editor (CBE) and adenine base editor (ABE) were reported to highly induce site-specific conversion of C:G-to-T:A or A:T-to-G:C with efficiency rates of 53%–88% or 44%–100%, respectively. The CBE and ABE systems provide a powerful route to efficiently introduce point mutations, with much less off-target effects than the DSB-based HR method, and could be effective methods to create rabbit models of human genetic diseases associated with single nucleotide variants.
The development of the programmable nucleases such as ZFNs, TALENs and the powerful CRISPR/Cas9 system has revolutionized the field of genome editing in rabbits. Meanwhile, challenges still remain that need to be overcome. A major concern and potential limitation of the genome editing nuclease system is the off-target effects, that is the mutations induced at sites other than the intended on-target site, which may lead to genetic instability and disrupt normal gene functions[123]. Although the off-target events reported so far are relatively very low in frequency, these studies do nevertheless serve as a timely reminder of the need for caution when the technology is proposed for human therapy. In animal model production, the off-target concerns are not as critical as in human therapy. Most studies in rabbits so far detected no or only minimal off-target mutations in the predicted sites, and the unintended mutations, if any, may be diluted by a serial breeding program. In a recent study, Keith Joung's lab proved that appropriately designed guide RNAs can direct efficient in vivo gene editing in mouse livers with no detectable off-target mutations as examined by deep sequencing[124–125]. Key tools and strategies for optimizing CRISPR-Cas9 genome editing specificity have been summarized in a review[126–128]. New mutation detection methods were employed to predict and analyze the potential off-target sites[128]. With carefully designed guide RNA and new versions of Cas9 protein with higher specificity, combined with a well-designed breeding program, off-target effects could be effectively avoided in rabbit model production.
In addition to the classic off-target events, which are caused by inaccurate recognition of the target sequence, a recent study[129] has found that the use of CRISPR-Cas9 had caused unintended on-target large deletions or rearrangements in as long as several thousand base pairs range, which may affect non-target genes or regulatory sequences around the target gene. These on-target large deletions or rearrangements, though in low frequency, may require carefully designed characterization to determine the exact nature of the mutation in the target gene. In animal models, using lines from different founder animals could minimize the potential effects of the unwanted on-target mutations, though it's a challenge in rabbit models due to cost. If possible, using tools that avoid DSB formation, such as base editors, may avoid these unwanted on-target damages. Engineered nucleases have been widely used to disrupt gene function by creating premature stop codons in target genes. Recently, several studies have reported unexpected exon skipping in gene-edited cells and mice generated with the CRISPR/Cas9 system, which partially preserve the wild-type gene function[130–132]. By analyzing 22 gene-edited rabbit lines generated with CRISPR/Cas9, Tingting Sui et al found evidence of exon skipping at relatively high frequency in rabbits, suggesting that CRISPR-mediated exon skipping depends on exon location[133]. In one of our KO rabbit model, although a specific small deletion of 10 bp on the first exon resulted in a premature stop codon, this small deletion made an upstream out-of-frame ATG to become in frame and produce a transcript that is only slightly different from the wild-type transcript at the 5′ end (unpublished data). These studies suggest the necessity of carefully performed genotyping, including sequencing, and expression validation of the rabbit models produced by nuclease mediated genome targeting.
The precise genome editing in rabbits has boomed within the past 4 years thanks to the newly developed CRISPR/Cas9 technology. The availability of the rabbit whole genome sequence[40,134] combined with the versatility of rabbit genome editing technology has greatly increased their value to biomedicine, motivating efforts to develop novel rabbit models that better replicate human disease to help 'bridge the gap between bench and bedside'. In the future, novel genomic engineered rabbit models will sustain the promise for understanding the pathophysiology of human disease and for development of new therapeutics.
| [1] |
Esteves PJ, Abrantes J, Baldauf HM, et al. The wide utility of rabbits as models of human diseases[J]. Exp Mol Med, 2018, 50: 1–10. doi: 10.1038/s12276-018-0094-1
|
| [2] |
Fan JL, Watanabe T. Transgenic rabbits as therapeutic protein bioreactors and human disease models[J]. Pharmacol Ther, 2003, 99(3): 261–282. doi: 10.1016/S0163-7258(03)00069-X
|
| [3] |
Peng XW. Transgenic rabbit models for studying human cardiovascular diseases[J]. Comp Med, 2012, 62(6): 472–429. https://pubmed.ncbi.nlm.nih.gov/23561880/
|
| [4] |
Peng XW, Knouse JA, Hernon KM. Rabbit models for studying human infectious diseases[J]. Comp Med, 2015, 65(6): 499–507. https://pubmed.ncbi.nlm.nih.gov/26678367/
|
| [5] |
Fan JL, Kitajima S, Watanabe T, et al. Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine[J]. Pharmacol Ther, 2015, 146: 104–119. doi: 10.1016/j.pharmthera.2014.09.009
|
| [6] |
Li WH, Gouy M, Sharp PM, et al. Molecular phylogeny of Rodentia, Lagomorpha, Primates, Artiodactyla, and Carnivora and molecular clocks[J]. Proc Natl Acad Sci U S A, 1990, 87(17): 6703–6707. doi: 10.1073/pnas.87.17.6703
|
| [7] |
Graur D, Duret L, Gouy M. Phylogenetic position of the order Lagomorpha (rabbits, hares and allies)[J]. Nature, 1996, 379(6563): 333–335. doi: 10.1038/379333a0
|
| [8] |
Pearce J. Louis Pasteur and rabies: a brief note[J]. J Neurol Neurosurg Psychiatry, 2002, 73(1): 82. doi: 10.1136/jnnp.73.1.82
|
| [9] |
Cambau E, Drancourt M. Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882[J]. Clin Microbiol Infect, 2014, 20(3): 196–201. doi: 10.1111/1469-0691.12555
|
| [10] |
Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis—Lessons from an animal counterpart of familial hypercholesterolemia[J]. N Engl J Med, 1983, 309(5): 288–296. doi: 10.1056/NEJM198308043090507
|
| [11] |
Endo A. Regulation of cholesterol synthesis, as focused on the regulation of HMG-CoA reductase (author's transl)[J]. Seikagaku (in Japanese), 1980, 52(10): 1033–1049.
|
| [12] |
Biggers JD. Walter Heape, FRS: a pioneer in reproductive biology. Centenary of his embryo transfer experiments[J]. J Reprod Fert, 1991, 93(1): 173–186. doi: 10.1530/jrf.0.0930173
|
| [13] |
Chang MC. Fertilization of rabbit ova in vitro[J]. Nature, 1959, 184(4684): 466–467. doi: 10.1038/184466a0
|
| [14] |
Hammer RE, Pursel VG, Rexroad CE Jr, et al. Production of transgenic rabbits, sheep and pigs by microinjection[J]. Nature, 1985, 315(6021): 680–683. doi: 10.1038/315680a0
|
| [15] |
Zernii EY, Baksheeva VE, Iomdina EN, et al. Rabbit models of ocular diseases: new relevance for classical approaches[J]. CNS Neurol Disord Drug Targets, 2016, 15(3): 267–291. doi: 10.2174/1871527315666151110124957
|
| [16] |
Kamaruzaman NA, Kardia E, Kamaldin N, et al. The rabbit as a model for studying lung disease and stem cell therapy[J]. Biomed Res Int, 2013, 2013: 691830.
|
| [17] |
Burkholder TH, Linton G, Hoyt RF Jr, et al. The rabbit as an experimental model[M]//Suckow MA, Stevens KA, Wilson RP. The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents. Boston: Academic Press, 2012: 529–560.
|
| [18] |
Christensen ND, Peng XW. Rabbit genetics and transgenic models[M]//Suckow MA, Stevens KA, Wilson RP. The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents. Boston: Academic Press, 2012: 165–193.
|
| [19] |
Isola LM, Gordon JW. Transgenic animals: a new era in developmental biology and medicine[J]. Biotechnology, 1991, 16: 3–20. https://pubmed.ncbi.nlm.nih.gov/2007198/
|
| [20] |
Gordon JW, Scangos GA, Plotkin DJ, et al. Genetic transformation of mouse embryos by microinjection of purified DNA[J]. Proc Natl Acad Sci U S A, 1980, 77(12): 7380–7384. doi: 10.1073/pnas.77.12.7380
|
| [21] |
Brinster RL, Chen HY, Trumbauer M, et al. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs[J]. Cell, 1981, 27(1): 223–231. doi: 10.1016/0092-8674(81)90376-7
|
| [22] |
Costantini F, Lacy E. Introduction of a rabbit β-globin gene into the mouse germ line[J]. Nature, 1981, 294(5836): 92–94. doi: 10.1038/294092a0
|
| [23] |
Gordon JW, Ruddle FH. Integration and stable germ line transmission of genes injected into mouse pronuclei[J]. Science, 1981, 214(4526): 1244–1246. doi: 10.1126/science.6272397
|
| [24] |
Wagner EF, Stewart TA, Mintz B. The human beta-globin gene and a functional viral thymidine kinase gene in developing mice[J]. Proc Natl Acad Sci U S A, 1981, 78(8): 5016–5020. doi: 10.1073/pnas.78.8.5016
|
| [25] |
Wagner TE, Hoppe PC, Jollick JD, et al. Microinjection of a rabbit beta-globin gene into zygotes and its subsequent expression in adult mice and their offspring[J]. Proc Natl Acad Sci U S A, 1981, 78(10): 6376–6380. doi: 10.1073/pnas.78.10.6376
|
| [26] |
Campbell KHS, McWhir J, Ritchie WA, et al. Sheep cloned by nuclear transfer from a cultured cell line[J]. Nature, 1996, 380(6569): 64–66. doi: 10.1038/380064a0
|
| [27] |
Bibikova M, Golic M, Golic KG, et al. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases[J]. Genetics, 2002, 161(3): 1169–1175. https://pubmed.ncbi.nlm.nih.gov/12136019/
|
| [28] |
Chesne P, Adenot PG, Viglietta C, et al. Cloned rabbits produced by nuclear transfer from adult somatic cells[J]. Nat Biotechnol, 2002, 20(4): 366–369. doi: 10.1038/nbt0402-366
|
| [29] |
Li SG, Guo Y, Shi JJ, et al. Transgene expression of enhanced green fluorescent protein in cloned rabbits generated from in vitro-transfected adult fibroblasts[J]. Transgenic Res, 2009, 18(2): 227–235. doi: 10.1007/s11248-008-9227-y
|
| [30] |
Geurts AM, Cost GJ, Freyvert Y, et al. Knockout rats via embryo microinjection of zinc-finger nucleases[J]. Science, 2009, 325(5939): 433. doi: 10.1126/science.1172447
|
| [31] |
Flisikowska T, Thorey IS, Offner S, et al. Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases[J]. PLoS One, 2011, 6(6): e21045. doi: 10.1371/journal.pone.0021045
|
| [32] |
Tesson L, Usal C, Menoret S, et al. Knockout rats generated by embryo microinjection of TALENs[J]. Nat Biotechnol, 2011, 29(8): 695–696. doi: 10.1038/nbt.1940
|
| [33] |
Gasiunas G, Barrangou R, Horvath P, et al. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria[J]. Proc Natl Acad Sci U S A, 2012, 109(39): E2579–E2586. doi: 10.1073/pnas.1208507109
|
| [34] |
Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity[J]. Science, 2012, 337(6096): 816–821. doi: 10.1126/science.1225829
|
| [35] |
Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering[J]. Cell, 2013, 153(4): 910–918. doi: 10.1016/j.cell.2013.04.025
|
| [36] |
Song J, Zhong J, Guo XG, et al. Generation of RAG 1- and 2-deficient rabbits by embryo microinjection of TALENs[J]. Cell Res, 2013, 23(8): 1059–1062. doi: 10.1038/cr.2013.85
|
| [37] |
Yang D, Xu J, Zhu T, et al. Effective gene targeting in rabbits using RNA-guided Cas9 nucleases[J]. J Mol Cell Biol, 2014, 6(1): 97–99. doi: 10.1093/jmcb/mjt047
|
| [38] |
Carneiro M, Rubin CJ, Di Palma F, et al. Rabbit genome analysis reveals a polygenic basis for phenotypic change during domestication[J]. Science, 2014, 345(6200): 1074–1079. doi: 10.1126/science.1253714
|
| [39] |
Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage[J]. Nature, 2016, 533(7603): 420–424. doi: 10.1038/nature17946
|
| [40] |
Wang Z, Zhang JF, Li H, et al. Hyperlipidemia-associated gene variations and expression patterns revealed by whole-genome and transcriptome sequencing of rabbit models[J]. Sci Rep, 2016, 6: 26942. doi: 10.1038/srep26942
|
| [41] |
Liu Z, Chen M, Chen S, et al. Highly efficient RNA-guided base editing in rabbit[J]. Nat Commun, 2018, 9(1): 2717. doi: 10.1038/s41467-018-05232-2
|
| [42] |
Shen W, Li L, Pan QJ, et al. Efficient and simple production of transgenic mice and rabbits using the new DMSO-sperm mediated exogenous DNA transfer method[J]. Mol Reprod Dev, 2006, 73(5): 589–594. doi: 10.1002/mrd.20401
|
| [43] |
Hiripi L, Negre D, Cosset FL, et al. Transgenic rabbit production with simian immunodeficiency virus-derived lentiviral vector[J]. Transgenic Res, 2010, 19(5): 799–808. doi: 10.1007/s11248-009-9356-y
|
| [44] |
Smith KR. Sperm-mediated gene transfer: concepts and controversies[M]. Sharjah, UAE: Bentham Science, 2012.
|
| [45] |
Kuznetsov AV, Kuznetsova IV, Schit IY. DNA interaction with rabbit sperm cells and its transfer into ova in vitro and in vivo[J]. Mol Reprod Dev, 2000, 56(S2): 292–297. doi: 10.1002/(SICI)1098-2795(200006)56:2+<292::AID-MRD18>3.0.CO;2-Z
|
| [46] |
Houdebine LM. The methods to generate transgenic animals and to control transgene expression[J]. J Biotechnol, 2002, 98(2-3): 145–160. doi: 10.1016/S0168-1656(02)00129-3
|
| [47] |
Katter K, Geurts AM, Hoffmann O, et al. Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbits[J]. FASEB J, 2013, 27(3): 930–941. doi: 10.1096/fj.12-205526
|
| [48] |
Ivics Z, Hiripi L, Hoffmann OI, et al. Germline transgenesis in rabbits by pronuclear microinjection of Sleeping beauty transposons[J]. Nat Protoc, 2014, 9(4): 794–809. doi: 10.1038/nprot.2014.009
|
| [49] |
Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos[J]. Nature, 1981, 292(5819): 154–156. doi: 10.1038/292154a0
|
| [50] |
Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells[J]. Proc Natl Acad Sci U S A, 1981, 78(12): 7634–7638. doi: 10.1073/pnas.78.12.7634
|
| [51] |
Gossler A, Doetschman T, Korn R, et al. Transgenesis by means of blastocyst-derived embryonic stem cell lines[J]. Proc Natl Acad Sci U S A, 1986, 83(23): 9065–9069. doi: 10.1073/pnas.83.23.9065
|
| [52] |
Robertson E, Bradley A, Kuehn M, et al. Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector[J]. Nature, 1986, 323(6087): 445–448. doi: 10.1038/323445a0
|
| [53] |
Kuehn MR, Bradley A, Robertson EJ, et al. A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice[J]. Nature, 1987, 326(6110): 295–298. doi: 10.1038/326295a0
|
| [54] |
Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells[J]. Nature, 2007, 448(7151): 313–317. doi: 10.1038/nature05934
|
| [55] |
Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state[J]. Nature, 2007, 448(7151): 318–324. doi: 10.1038/nature05944
|
| [56] |
Boland MJ, Hazen JL, Nazor KL, et al. Adult mice generated from induced pluripotent stem cells[J]. Nature, 2009, 461(7260): 91–94. doi: 10.1038/nature08310
|
| [57] |
Kang L, Wang JL, Zhang Y, et al. iPS cells can support full-term development of tetraploid blastocyst-complemented embryos[J]. Cell Stem Cell, 2009, 5(2): 135–138. doi: 10.1016/j.stem.2009.07.001
|
| [58] |
Zhao XY, Li W, Lv Z, et al. iPS cells produce viable mice through tetraploid complementation[J]. Nature, 2009, 461(7260): 86–90. doi: 10.1038/nature08267
|
| [59] |
Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century[J]. Nat Rev Genet, 2005, 6(6): 507–512. doi: 10.1038/nrg1619
|
| [60] |
Fang ZF, Gai H, Huang YZ, et al. Rabbit embryonic stem cell lines derived from fertilized, parthenogenetic or somatic cell nuclear transfer embryos[J]. Exp Cell Res, 2006, 312(18): 3669–3682. doi: 10.1016/j.yexcr.2006.08.013
|
| [61] |
Wang SF, Tang XH, Niu YY, et al. Generation and characterization of rabbit embryonic stem cells[J]. Stem Cells, 2007, 25(2): 481–489. doi: 10.1634/stemcells.2006-0226
|
| [62] |
Honda A, Hirose M, Inoue K, et al. Stable embryonic stem cell lines in rabbits: potential small animal models for human research[J]. Reprod Biomed Online, 2008, 17(5): 706–715. doi: 10.1016/S1472-6483(10)60320-3
|
| [63] |
Osteil P, Tapponnier Y, Markossian S, et al. Induced pluripotent stem cells derived from rabbits exhibit some characteristics of naïve pluripotency[J]. Biol Open, 2013, 2(6): 613–628. doi: 10.1242/bio.20134242
|
| [64] |
Xue F, Ma YH, Chen YE, et al. Recombinant rabbit leukemia inhibitory factor and rabbit embryonic fibroblasts support the derivation and maintenance of rabbit embryonic stem cells[J]. Cell Reprogram, 2012, 14(4): 364–376. doi: 10.1089/cell.2012.0001
|
| [65] |
Du FL, Chen CH, Li Y, et al. Derivation of rabbit embryonic stem cells from vitrified-thawed embryos[J]. Cell Reprogram, 2015, 17(6): 453–462. doi: 10.1089/cell.2015.0044
|
| [66] |
Zakhartchenko V, Flisikowska T, Li S, et al. Cell-mediated transgenesis in rabbits: chimeric and nuclear transfer animals[J]. Biol Reprod, 2011, 84(2): 229–237. doi: 10.1095/biolreprod.110.087098
|
| [67] |
Tancos Z, Nemes C, Polgar Z, et al. Generation of rabbit pluripotent stem cell lines[J]. Theriogenology, 2012, 78(8): 1774–1786. doi: 10.1016/j.theriogenology.2012.06.017
|
| [68] |
McCreath KJ, Howcroft J, Campbell KHS, et al. Production of gene-targeted sheep by nuclear transfer from cultured somatic cells[J]. Nature, 2000, 405(6790): 1066–1069. doi: 10.1038/35016604
|
| [69] |
Lai LX, Kolber-Simonds D, Park KW, et al. Production of α-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning[J]. Science, 2002, 295(5557): 1089–1092. doi: 10.1126/science.1068228
|
| [70] |
Richt JA, Kasinathan P, Hamir AN, et al. Production of cattle lacking prion protein[J]. Nat Biotechnol, 2007, 25(1): 132–138. doi: 10.1038/nbt1271
|
| [71] |
Stice SL, Robl JM. Nuclear reprogramming in nuclear transplant rabbit embryos[J]. Biol Reprod, 1988, 39(3): 657–664. doi: 10.1095/biolreprod39.3.657
|
| [72] |
Du FL, Xu J, Zhang JF, et al. Beneficial effect of young oocytes for rabbit somatic cell nuclear transfer[J]. Cloning Stem Cells, 2009, 11(1): 131–140. doi: 10.1089/clo.2008.0042
|
| [73] |
Li SG, Chen XJ, Fang ZF, et al. Rabbits generated from fibroblasts through nuclear transfer[J]. Reproduction, 2006, 131(6): 1085–1090. doi: 10.1530/rep.1.01065
|
| [74] |
Li SG, Flisikowska T, Kessler B, et al. Production of cloned transgenic rabbits from mesenchymal stem cells[J]. Reprod Fertil Dev, 2010, 22(1): 192–192. doi: 10.1071/RDv22n1Ab67
|
| [75] |
Yin MR, Jiang WH, Fang ZF, et al. Generation of hypoxanthine phosphoribosyltransferase gene knockout rabbits by homologous recombination and gene trapping through somatic cell nuclear transfer[J]. Sci Rep, 2015, 5: 16023. doi: 10.1038/srep16023
|
| [76] |
Gaj T, Gersbach CA, Barbas III CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering[J]. Trends Biotechnol, 2013, 31(7): 397–405. doi: 10.1016/j.tibtech.2013.04.004
|
| [77] |
Conklin BR. Sculpting genomes with a hammer and chisel[J]. Nat Methods, 2013, 10(9): 839–840. doi: 10.1038/nmeth.2608
|
| [78] |
Cui XX, Ji DA, Fisher DA, et al. Targeted integration in rat and mouse embryos with zinc-finger nucleases[J]. Nat Biotechnol, 2011, 29(1): 64–67. doi: 10.1038/nbt.1731
|
| [79] |
Paques F, Duchateau P. Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy[J]. Curr Gene Ther, 2007, 7(1): 49–66. doi: 10.2174/156652307779940216
|
| [80] |
Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain[J]. Proc Natl Acad Sci U S A, 1996, 93(3): 1156–1160. doi: 10.1073/pnas.93.3.1156
|
| [81] |
Yang DS, Yang HQ, Li W, et al. Generation of PPARγ mono-allelic knockout pigs via zinc-finger nucleases and nuclear transfer cloning[J]. Cell Res, 2011, 21(6): 979–982. doi: 10.1038/cr.2011.70
|
| [82] |
Yu SL, Luo JJ, Song ZY, et al. Highly efficient modification of beta-lactoglobulin (BLG) gene via zinc-finger nucleases in cattle[J]. Cell Res, 2011, 21(11): 1638–1640. doi: 10.1038/cr.2011.153
|
| [83] |
Perez EE, Wang JB, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases[J]. Nat Biotechnol, 2008, 26(7): 808–816. doi: 10.1038/nbt1410
|
| [84] |
Meng XD, Noyes MB, Zhu LJ, et al. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases[J]. Nat Biotechnol, 2008, 26(6): 695–701. doi: 10.1038/nbt1398
|
| [85] |
Yang DS, Zhang JF, Xu J, et al. Production of apolipoprotein C-III knockout rabbits using zinc finger nucleases[J]. J Vis Exp, 2013, (81): e50957. doi: 10.3791/50957
|
| [86] |
Ji DA, Zhao GJ, Songstad A, et al. Efficient creation of an APOE knockout rabbit[J]. Transgenic Res, 2015, 24(2): 227–235. doi: 10.1007/s11248-014-9834-8
|
| [87] |
Niimi M, Yang DS, Kitajima S, et al. ApoE knockout rabbits: a novel model for the study of human hyperlipidemia[J]. Atherosclerosis, 2016, 245: 187–193. doi: 10.1016/j.atherosclerosis.2015.12.002
|
| [88] |
Zhang JF, Niimi M, Yang DS, et al. Deficiency of cholesteryl ester transfer protein protects against atherosclerosis in rabbits[J]. Arterioscler Thromb Vasc Biol, 2017, 37(6): 1068–1075. doi: 10.1161/ATVBAHA.117.309114
|
| [89] |
Miller JC, Tan SY, Qiao GJ, et al. A TALE nuclease architecture for efficient genome editing[J]. Nat Biotechnol, 2011, 29(2): 143–148. doi: 10.1038/nbt.1755
|
| [90] |
Christian M, Cermak T, Doyle EL, et al. Targeting DNA double-strand breaks with TAL effector nucleases[J]. Genetics, 2010, 186(2): 757–761. doi: 10.1534/genetics.110.120717
|
| [91] |
Boch J, Scholze H, Schornack S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors[J]. Science, 2009, 326(5959): 1509–1512. doi: 10.1126/science.1178811
|
| [92] |
Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors[J]. Science, 2009, 326(5959): 1501. doi: 10.1126/science.1178817
|
| [93] |
Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering[J]. Cell, 2014, 157(6): 1262–1278. doi: 10.1016/j.cell.2014.05.010
|
| [94] |
Yang DS, Xu J, Chen YE. Generation of rabbit models by gene editing nucleases[M]//Liu CY, Du YB. Microinjection. New York: Humana Press, 2019: 327–345.
|
| [95] |
Li L, Zhang QJ, Yang HQ, et al. Fumarylacetoacetate hydrolase knock-out rabbit model for hereditary tyrosinemia type 1[J]. J Biol Chem, 2017, 292(11): 4755–4763. doi: 10.1074/jbc.M116.764787
|
| [96] |
Chen M, Yao B, Yang QB, et al. Truncated C-terminus of fibrillin-1 induces Marfanoid-progeroid-lipodystrophy (MPL) syndrome in rabbit[J]. Dis Model Mech, 2018, 11(4): dmm031542. doi: 10.1242/dmm.031542
|
| [97] |
Sui TT, Lau YS, Liu D, et al. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9[J]. Dis Model Mech, 2018, 11(6): dmm032201. doi: 10.1242/dmm.032201
|
| [98] |
Sui TT, Xu L, Lau YS, et al. Development of muscular dystrophy in a CRISPR-engineered mutant rabbit model with frame-disrupting ANO5 mutations[J]. Cell Death Dis, 2018, 9(6): 609. doi: 10.1038/s41419-018-0674-y
|
| [99] |
Yuan L, Yao HB, Xu YX, et al. CRISPR/cas9-mediated mutation of αA-crystallin gene induces congenital cataracts in rabbits[J]. Invest Ophthalmol Vis Sci, 2017, 58(6): BIO34–BIO41. doi: 10.1167/iovs.16-21287
|
| [100] |
Yuan L, Sui TT, Chen M, et al. CRISPR/Cas9-mediated GJA8 knockout in rabbits recapitulates human congenital cataracts[J]. Sci Rep, 2016, 6: 22024. doi: 10.1038/srep22024
|
| [101] |
Lu R, Yuan T, Wang Y, et al. Spontaneous severe hypercholesterolemia and atherosclerosis lesions in rabbits with deficiency of low-density lipoprotein receptor (LDLR) on exon 7[J]. EBioMedicine, 2018, 36: 29–38. doi: 10.1016/j.ebiom.2018.09.020
|
| [102] |
Guo R, Wan Y, Xu D, et al. Generation and evaluation of Myostatin knock-out rabbits and goats using CRISPR/Cas9 system[J]. Sci Rep, 2016, 6: 29855. doi: 10.1038/srep29855
|
| [103] |
Lv Q, Yuan L, Deng J, et al. Efficient Generation of Myostatin Gene Mutated Rabbit by CRISPR/Cas9[J]. Sci Rep, 2016, 6: 25029. doi: 10.1038/srep25029
|
| [104] |
Song Y, Liu T, Wang Y, et al. Mutation of the Sp1 binding site in the 5' flanking region of SRY causes sex reversal in rabbits[J]. Oncotarget, 2017, 8(24): 38176–38183. doi: 10.18632/oncotarget.16979
|
| [105] |
Song Y, Xu Y, Liang M, et al. CRISPR/Cas9-mediated mosaic mutation of SRY gene induces hermaphroditism in rabbits[J]. Biosci Rep, 2018, 38(2): BSR20171490. doi: 10.1042/BSR20171490
|
| [106] |
Sui T, Yuan L, Liu H, et al. CRISPR/Cas9-mediated mutation of PHEX in rabbit recapitulates human X-linked hypophosphatemia (XLH)[J]. Hum Mol Genet, 2016, 25(13): 2661–2671. doi: 10.1093/hmg/ddw125
|
| [107] |
Sui T, Liu D, Liu T, et al. LMNA-mutated rabbits: a model of premature aging syndrome with muscular dystrophy and dilated cardiomyopathy[J]. Aging Dis, 2019, 10(1): 102–115. doi: 10.14336/AD.2018.0209
|
| [108] |
Wu H, Liu Q, Shi H, et al. Engineering CRISPR/Cpf1 with tRNA promotes genome editing capability in mammalian systems[J]. Cell Mol Life Sci, 2018, 75(19): 3593–3607. doi: 10.1007/s00018-018-2810-3
|
| [109] |
Honda A, Hirose M, Sankai T, et al. Single-step generation of rabbits carrying a targeted allele of the tyrosinase gene using CRISPR/Cas9[J]. Exp Anim, 2015, 64(1): 31–37. doi: 10.1538/expanim.14-0034
|
| [110] |
Song Y, Xu Y, Deng J, et al. CRISPR/Cas9-mediated mutation of tyrosinase (Tyr) 3' UTR induce graying in rabbit[J]. Sci Rep, 2017, 7(1): 1569. doi: 10.1038/s41598-017-01727-y
|
| [111] |
Jiang WH, Liu LL, Chang QR, et al. Production of Wilson disease model rabbits with homology-directed precision point mutations in the ATP7B gene using the CRISPR/Cas9 system[J]. Sci Rep, 2018, 8: 1332. doi: 10.1038/s41598-018-19774-4
|
| [112] |
Song YN, Zhang YX, Chen M, et al. Functional validation of the albinism-associated tyrosinase T373K SNP by CRISPR/Cas9-mediated homology-directed repair (HDR) in rabbits[J]. EBioMedicine, 2018, 36: 517–525. doi: 10.1016/j.ebiom.2018.09.041
|
| [113] |
Song YN, Yuan L, Wang Y, et al. Efficient dual sgRNA-directed large gene deletion in rabbit with CRISPR/Cas9 system[J]. Cell Mol Life Sci, 2016, 73(15): 2959–2968. doi: 10.1007/s00018-016-2143-z
|
| [114] |
Song J, Wang GS, Hoenerhoff MJ, et al. Bacterial and Pneumocystis infections in the lungs of gene-knockout rabbits with severe combined immunodeficiency[J]. Front Immunol, 2018, 9: 429. doi: 10.3389/fimmu.2018.00429
|
| [115] |
Song J, Yang DS, Ruan JX, et al. Production of immunodeficient rabbits by multiplex embryo transfer and multiplex gene targeting[J]. Sci Rep, 2017, 7(1): 12202. doi: 10.1038/s41598-017-12201-0
|
| [116] |
Yan Q, Zhang Q, Yang H, et al. Generation of multi-gene knockout rabbits using the Cas9/gRNA system[J]. Cell Regen (Lond), 2014, 3(1): 12. doi: 10.1186/2045-9769-3-12
|
| [117] |
Liu H, Sui T, Liu D, et al. Multiple homologous genes knockout (KO) by CRISPR/Cas9 system in rabbit[J]. Gene, 2018, 647: 261–267. doi: 10.1016/j.gene.2018.01.044
|
| [118] |
Yang DS, Song J, Zhang JF, et al. Identification and characterization of rabbit ROSA26 for gene knock-in and stable reporter gene expression[J]. Sci Rep, 2016, 6: 25161. doi: 10.1038/srep25161
|
| [119] |
Song J, Yang DS, Xu J, et al. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency[J]. Nat Commun, 2016, 7: 10548. doi: 10.1038/ncomms10548
|
| [120] |
Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage[J]. Nature, 2017, 551(7681): 464–471. doi: 10.1038/nature24644
|
| [121] |
Komor AC, Zhao KT, Packer MS, et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C: G-to-T: a base editors with higher efficiency and product purity[J]. Sci Adv, 2017, 3(8): eaao4774. doi: 10.1126/sciadv.aao4774
|
| [122] |
Koblan LW, Doman JL, Wilson C, et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction[J]. Nat Biotechnol, 2018, 36(9): 843–846. doi: 10.1038/nbt.4172
|
| [123] |
Hsu PD, Scott DA, Weinstein JA, et al. DNA targeting specificity of RNA-guided Cas9 nucleases[J]. Nat Biotechnol, 2013, 31(9): 827–832. doi: 10.1038/nbt.2647
|
| [124] |
Schmid-Burgk JL, Gao LY, Li D, et al. Highly parallel profiling of cas9 variant specificity[J]. Mol Cell, 2020, . doi: 10.1016/j.molcel.2020.02.023
|
| [125] |
Tycko J, Myer VE, Hsu PD. Methods for optimizing crispr-cas9 genome editing specificity[J]. Mol Cell, 2016, 63(3): 355–370. doi: 10.1016/j.molcel.2016.07.004
|
| [126] |
Chen SM, Yao YF, Zhang YC, et al. CRISPR system: discovery, development and off-target detection[J]. Cell Signal, 2020, 70: 109577. doi: 10.1016/j.cellsig.2020.109577
|
| [127] |
Li JJ, Hong SY, Chen WJ, et al. Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing[J]. J Genet Genomics, 2019, 46(11): 513–521. doi: 10.1016/j.jgg.2019.11.002
|
| [128] |
Zischewski J, Fischer R, Bortesi L. Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases[J]. Biotechnol Adv, 2017, 35(1): 95–104. doi: 10.1016/j.biotechadv.2016.12.003
|
| [129] |
Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements[J]. Nat Biotechnol, 2018, 36(8): 765–771. doi: 10.1038/nbt.4192
|
| [130] |
Mou HW, Smith JL, Peng LT, et al. CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion[J]. Genome Biol, 2017, 18(1): 108. doi: 10.1186/s13059-017-1237-8
|
| [131] |
Prykhozhij SV, Steele SL, Razaghi B, et al. A rapid and effective method for screening, sequencing and reporter verification of engineered frameshift mutations in zebrafish[J]. Dis Model Mech, 2017, 10(6): 811–822. doi: 10.1242/dmm.026765
|
| [132] |
Sharpe JJ, Cooper TA. Unexpected consequences: exon skipping caused by CRISPR-generated mutations[J]. Genome Biol, 2017, 18(1): 109. doi: 10.1186/s13059-017-1240-0
|
| [133] |
Sui TT, Song YN, Liu ZQ, et al. CRISPR-induced exon skipping is dependent on premature termination codon mutations[J]. Genome Biol, 2018, 19(1): 164. doi: 10.1186/s13059-018-1532-z
|
| [134] |
Li P, Estrada J, Zhang F, et al. Isolation, characterization, and nuclear reprogramming of cell lines derived from porcine adult liver and fat[J]. Cell Reprogram, 2010, 12(5): 599–607. doi: 10.1089/cell.2010.0006
|
| [1] | Desaulniers Amy T., Cederberg Rebecca A., Carreiro Elizabeth P., Gurumurthy Channabasavaiah B., White Brett R.. A transgenic pig model expressing a CMV-ZsGreen1 reporter across an extensive array of tissues[J]. The Journal of Biomedical Research, 2021, 35(2): 163-173. DOI: 10.7555/JBR.34.20200111 |
| [2] | Konishi Colin T., Long Chengzu. Progress and challenges in CRISPR-mediated therapeutic genome editing for monogenic diseases[J]. The Journal of Biomedical Research, 2021, 35(2): 148-162. DOI: 10.7555/JBR.34.20200105 |
| [3] | Papizan James B., Porter Shaina N., Sharma Akshay, Pruett-Miller Shondra M.. Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies[J]. The Journal of Biomedical Research, 2021, 35(2): 115-134. DOI: 10.7555/JBR.34.20200096 |
| [4] | Choe Dongwook C., Musunuru Kiran. Base editing: a brief review and a practical example[J]. The Journal of Biomedical Research, 2021, 35(2): 107-114. DOI: 10.7555/JBR.34.20200003 |
| [5] | McKay Alexander, Burgio Gaetan. Harnessing CRISPR-Cas system diversity for gene editing technologies[J]. The Journal of Biomedical Research, 2021, 35(2): 91-106. DOI: 10.7555/JBR.35.20200184 |
| [6] | Li Wanlin, Wu Min, Wang Qianqian, Xu Kun, Lin Fan, Wang Qianghu, Guo Renhua. A comparative genomics analysis of lung adenocarcinoma for Chinese population by using panel of recurrent mutations[J]. The Journal of Biomedical Research, 2021, 35(1): 11-20. DOI: 10.7555/JBR.34.20200068 |
| [7] | Ma Hongxia, Shen Hongbing. From human genome epidemiology to systems epidemiology: current progress and future perspective[J]. The Journal of Biomedical Research, 2020, 34(5): 323-327. DOI: 10.7555/JBR.34.20200027 |
| [8] | Niimi Manabu, Nishijima Kazutoshi, Kitajima Shuji, Matsuhisa Fumikazu, Satoh Kaneo, Yamazaki Hirokazu, Zhang Jifeng, Chen Y. Eugene, Fan Jianglin. Macrophage-derived matrix metalloproteinase-1 enhances aortic aneurysm formation in transgenic rabbits[J]. The Journal of Biomedical Research, 2019, 33(4): 271-279. DOI: 10.7555/JBR.33.20180097 |
| [9] | Didi Zhu, Jiamin Yuan, Rui Zhu, Yao Wang, Zhiyong Qian, Jiangang Zou. Pathway-based analysis of genome-wide association study of circadian phenotypes[J]. The Journal of Biomedical Research, 2018, 32(5): 361-370. DOI: 10.7555/JBR.32.20170102 |
| [10] | Honggang Yi, Hongmei Wo, Yang Zhao, Ruyang Zhang, Junchen Dai, Guangfu Jin, Hongxia Ma, Tangchun Wu, Zhibin Hu, Dongxin Lin, Hongbing Shen, Feng Chen. Comparison of dimension reduction-based logistic regression models forcase-control genome-wide association study: principal components analysis vs. partial least squares[J]. The Journal of Biomedical Research, 2015, 29(4): 298-307. DOI: 10.7555/JBR.29.20140043 |
| 1. | Pan S, Yan H, Zhu J, et al. GYY4137, as a slow-releasing H2S donor, ameliorates sodium deoxycholate-induced chronic intestinal barrier injury and gut microbiota dysbiosis. Front Pharmacol, 2024, 15: 1476407. DOI:10.3389/fphar.2024.1476407 |
| 2. | Jin YQ, Yuan H, Liu YF, et al. Role of hydrogen sulfide in health and disease. MedComm (2020), 2024, 5(9): e661. DOI:10.1002/mco2.661 |
| 3. | Sun X, Wu S, Mao C, et al. Therapeutic Potential of Hydrogen Sulfide in Ischemia and Reperfusion Injury. Biomolecules, 2024, 14(7): 740. DOI:10.3390/biom14070740 |
| 4. | Pagliaro P, Weber NC, Femminò S, et al. Gasotransmitters and noble gases in cardioprotection: unraveling molecular pathways for future therapeutic strategies. Basic Res Cardiol, 2024, 119(4): 509-544. DOI:10.1007/s00395-024-01061-1 |
| 5. | Dugbartey GJ, Juriasingani S, Richard-Mohamed M, et al. Static Cold Storage with Mitochondria-Targeted Hydrogen Sulfide Donor Improves Renal Graft Function in an Ex Vivo Porcine Model of Controlled Donation-after-Cardiac-Death Kidney Transplantation. Int J Mol Sci, 2023, 24(18): 14017. DOI:10.3390/ijms241814017 |
| 6. | Hu Q, Lukesh JC 3rd. H2S Donors with Cytoprotective Effects in Models of MI/R Injury and Chemotherapy-Induced Cardiotoxicity. Antioxidants (Basel), 2023, 12(3): 650. DOI:10.3390/antiox12030650 |
| 7. | Farzaei MH, Ramezani-Aliakbari F, Ramezani-Aliakbari M, et al. Regulatory effects of trimetazidine in cardiac ischemia/reperfusion injury. Naunyn Schmiedebergs Arch Pharmacol, 2023, 396(8): 1633-1646. DOI:10.1007/s00210-023-02469-7 |
| 8. | Khattak S, Rauf MA, Khan NH, et al. Hydrogen Sulfide Biology and Its Role in Cancer. Molecules, 2022, 27(11): 3389. DOI:10.3390/molecules27113389 |
| 9. | Zhou M, Chen JY, Chao ML, et al. S-nitrosylation of c-Jun N-terminal kinase mediates pressure overload-induced cardiac dysfunction and fibrosis. Acta Pharmacol Sin, 2022, 43(3): 602-612. DOI:10.1038/s41401-021-00674-9 |
| 10. | Zhang Y, Gong W, Xu M, et al. Necroptosis Inhibition by Hydrogen Sulfide Alleviated Hypoxia-Induced Cardiac Fibroblasts Proliferation via Sirtuin 3. Int J Mol Sci, 2021, 22(21): 11893. DOI:10.3390/ijms222111893 |
| 11. | McCook O, Denoix N, Radermacher P, et al. H2S and Oxytocin Systems in Early Life Stress and Cardiovascular Disease. J Clin Med, 2021, 10(16): 3484. DOI:10.3390/jcm10163484 |
| 12. | Testai L, Brancaleone V, Flori L, et al. Modulation of EndMT by Hydrogen Sulfide in the Prevention of Cardiovascular Fibrosis. Antioxidants (Basel), 2021, 10(6): 910. DOI:10.3390/antiox10060910 |
| 13. | Wang WL, Ge TY, Chen X, et al. Advances in the Protective Mechanism of NO, H2S, and H2 in Myocardial Ischemic Injury. Front Cardiovasc Med, 2020, 7: 588206. DOI:10.3389/fcvm.2020.588206 |
| 14. | Denoix N, McCook O, Ecker S, et al. The Interaction of the Endogenous Hydrogen Sulfide and Oxytocin Systems in Fluid Regulation and the Cardiovascular System. Antioxidants (Basel), 2020, 9(8): 748. DOI:10.3390/antiox9080748 |
| 15. | Pieretti JC, Junho CVC, Carneiro-Ramos MS, et al. H2S- and NO-releasing gasotransmitter platform: A crosstalk signaling pathway in the treatment of acute kidney injury. Pharmacol Res, 2020, 161: 105121. DOI:10.1016/j.phrs.2020.105121 |
| 16. | Chen LJ, Ning JZ, Cheng F, et al. Comparison of Intraperitoneal and Intratesticular GYY4137 Therapy for the Treatment of Testicular Ischemia Reperfusion Injury in Rats. Curr Med Sci, 2020, 40(2): 332-338. DOI:10.1007/s11596-020-2180-6 |
| 17. | Yurinskaya MM, Krasnov GS, Kulikova DA, et al. H2S counteracts proinflammatory effects of LPS through modulation of multiple pathways in human cells. Inflamm Res, 2020, 69(5): 481-495. DOI:10.1007/s00011-020-01329-x |
| 18. | Kang SC, Sohn EH, Lee SR. Hydrogen Sulfide as a Potential Alternative for the Treatment of Myocardial Fibrosis. Oxid Med Cell Longev, 2020, 2020: 4105382. DOI:10.1155/2020/4105382 |
| 19. | Soo E, Marsh C, Steiner R, et al. Optimizing organs for transplantation; advancements in perfusion and preservation methods. Transplant Rev (Orlando), 2020, 34(1): 100514. DOI:10.1016/j.trre.2019.100514 |
| 20. | Zheng Q, Pan L, Ji Y. H 2S protects against diabetes-accelerated atherosclerosis by preventing the activation of NLRP3 inflammasome. J Biomed Res, 2019, 34(2): 94-102. DOI:10.7555/JBR.33.20190071 |
| 21. | Newton TD, Pluth MD. Development of a hydrolysis-based small-molecule hydrogen selenide (H2Se) donor. Chem Sci, 2019, 10(46): 10723-10727. DOI:10.1039/c9sc04616j |
| 22. | Luo H, Song S, Chen Y, et al. Inhibitor 1 of Protein Phosphatase 1 Regulates Ca2+/Calmodulin-Dependent Protein Kinase II to Alleviate Oxidative Stress in Hypoxia-Reoxygenation Injury of Cardiomyocytes. Oxid Med Cell Longev, 2019, 2019: 2193019. DOI:10.1155/2019/2193019 |
| 23. | Maassen H, Hendriks KDW, Venema LH, et al. Hydrogen sulphide-induced hypometabolism in human-sized porcine kidneys. PLoS One, 2019, 14(11): e0225152. DOI:10.1371/journal.pone.0225152 |
| 24. | Chen Z, Tang J, Wang P, et al. GYY4137 Attenuates Sodium Deoxycholate-Induced Intestinal Barrier Injury Both In Vitro and In Vivo. Biomed Res Int, 2019, 2019: 5752323. DOI:10.1155/2019/5752323 |
| 25. | Zheng W, Liu C. The cystathionine γ-lyase/hydrogen sulfide pathway mediates the trimetazidine-induced protection of H9c2 cells against hypoxia/reoxygenation-induced apoptosis and oxidative stress. Anatol J Cardiol, 2019, 22(3): 102-111. DOI:10.14744/AnatolJCardiol.2019.83648 |
| 26. | Van Dingenen J, Pieters L, Vral A, et al. The H2S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H2S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus. Front Pharmacol, 2019, 10: 116. DOI:10.3389/fphar.2019.00116 |
| 27. | Wang W, Liu H, Lu Y, et al. Controlled-releasing hydrogen sulfide donor based on dual-modal iron oxide nanoparticles protects myocardial tissue from ischemia-reperfusion injury. Int J Nanomedicine, 2019, 14: 875-888. DOI:10.2147/IJN.S186225 |
| 28. | Cao X, Zhang W, Moore PK, et al. Protective Smell of Hydrogen Sulfide and Polysulfide in Cisplatin-Induced Nephrotoxicity. Int J Mol Sci, 2019, 20(2): 313. DOI:10.3390/ijms20020313 |
| 29. | Cao X, Ding L, Xie ZZ, et al. A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer?. Antioxid Redox Signal, 2019, 31(1): 1-38. DOI:10.1089/ars.2017.7058 |
| 30. | Merz T, Lukaschewski B, Wigger D, et al. Interaction of the hydrogen sulfide system with the oxytocin system in the injured mouse heart. Intensive Care Med Exp, 2018, 6(1): 41. DOI:10.1186/s40635-018-0207-0 |
| 31. | Zhang L, Wang Y, Li Y, et al. Hydrogen Sulfide (H2S)-Releasing Compounds: Therapeutic Potential in Cardiovascular Diseases. Front Pharmacol, 2018, 9: 1066. DOI:10.3389/fphar.2018.01066 |
| 32. | Zhang Y, Liu X, Zhang L, et al. Metformin Protects against H2O2-Induced Cardiomyocyte Injury by Inhibiting the miR-1a-3p/GRP94 Pathway. Mol Ther Nucleic Acids, 2018, 13: 189-197. DOI:10.1016/j.omtn.2018.09.001 |
| 33. | Corsello T, Komaravelli N, Casola A. Role of Hydrogen Sulfide in NRF2- and Sirtuin-Dependent Maintenance of Cellular Redox Balance. Antioxidants (Basel), 2018, 7(10): 129. DOI:10.3390/antiox7100129 |
| 34. | Woods JJ, Cao J, Lippert AR, et al. Characterization and Biological Activity of a Hydrogen Sulfide-Releasing Red Light-Activated Ruthenium(II) Complex. J Am Chem Soc, 2018, 140(39): 12383-12387. DOI:10.1021/jacs.8b08695 |
| 35. | Zhou X, Tang S, Hu K, et al. DL-Propargylglycine protects against myocardial injury induced by chronic intermittent hypoxia through inhibition of endoplasmic reticulum stress. Sleep Breath, 2018, 22(3): 853-863. DOI:10.1007/s11325-018-1656-0 |
| 36. | Zeng C, Jiang W, Zheng R, et al. Cardioprotection of tilianin ameliorates myocardial ischemia-reperfusion injury: Role of the apoptotic signaling pathway. PLoS One, 2018, 13(3): e0193845. DOI:10.1371/journal.pone.0193845 |
| 37. | Ning JZ, Li W, Cheng F, et al. The protective effects of GYY4137 on ipsilateral testicular injury in experimentally varicocele-induced rats. Exp Ther Med, 2018, 15(1): 433-439. DOI:10.3892/etm.2017.5417 |
| 38. | Meng G, Zhao S, Xie L, et al. Protein S-sulfhydration by hydrogen sulfide in cardiovascular system. Br J Pharmacol, 2018, 175(8): 1146-1156. DOI:10.1111/bph.13825 |
| 39. |
Peng Q, Wang X, Wu K, et al. Irisin attenuates H2O2-induced apoptosis in cardiomyocytes via microRNA-19b/AKT/mTOR signaling pathway. Int J Clin Exp Pathol, 2017, 10(7): 7707-7717.
|
| 40. | Wang M, Tang W, Zhu YZ. An Update on AMPK in Hydrogen Sulfide Pharmacology. Front Pharmacol, 2017, 8: 810. DOI:10.3389/fphar.2017.00810 |
| 41. | Szabo C, Papapetropoulos A. International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. Pharmacol Rev, 2017, 69(4): 497-564. DOI:10.1124/pr.117.014050 |
| 42. | Pang Z, Zhao W, Yao Z. Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention. Med Sci Monit, 2017, 23: 2924-2930. DOI:10.12659/msm.902324 |
| 43. | Sun X, Wang W, Dai J, et al. A Long-Term and Slow-Releasing Hydrogen Sulfide Donor Protects against Myocardial Ischemia/Reperfusion Injury. Sci Rep, 2017, 7(1): 3541. DOI:10.1038/s41598-017-03941-0 |
| 44. | Sun Y, Huang Y, Yu W, et al. Sulfhydration-associated phosphodiesterase 5A dimerization mediates vasorelaxant effect of hydrogen sulfide. Oncotarget, 2017, 8(19): 31888-31900. DOI:10.18632/oncotarget.16649 |
| 45. | Yuan S, Shen X, Kevil CG. Beyond a Gasotransmitter: Hydrogen Sulfide and Polysulfide in Cardiovascular Health and Immune Response. Antioxid Redox Signal, 2017, 27(10): 634-653. DOI:10.1089/ars.2017.7096 |
| 46. | Magierowski M, Magierowska K, Hubalewska-Mazgaj M, et al. Exogenous and Endogenous Hydrogen Sulfide Protects Gastric Mucosa against the Formation and Time-Dependent Development of Ischemia/Reperfusion-Induced Acute Lesions Progressing into Deeper Ulcerations. Molecules, 2017, 22(2): 295. DOI:10.3390/molecules22020295 |
| 47. | Bazhanov N, Escaffre O, Freiberg AN, et al. Broad-Range Antiviral Activity of Hydrogen Sulfide Against Highly Pathogenic RNA Viruses. Sci Rep, 2017, 7: 41029. DOI:10.1038/srep41029 |
| 48. | Cao X, Bian JS. The Role of Hydrogen Sulfide in Renal System. Front Pharmacol, 2016, 7: 385. DOI:10.3389/fphar.2016.00385 |
| 49. | Dugbartey GJ, Peppone LJ, de Graaf IA. An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures. Toxicology, 2016, 371: 58-66. DOI:10.1016/j.tox.2016.10.001 |
| 50. | Haase T, Börnigen D, Müller C, et al. Systems Medicine as an Emerging Tool for Cardiovascular Genetics. Front Cardiovasc Med, 2016, 3: 27. DOI:10.3389/fcvm.2016.00027 |
| 51. | Tian XH, Liu CL, Jiang HL, et al. Cardioprotection provided by Echinatin against ischemia/reperfusion in isolated rat hearts. BMC Cardiovasc Disord, 2016, 16: 119. DOI:10.1186/s12872-016-0294-3 |
| 52. | Xu J, Tang Y, Bei Y, et al. miR-19b attenuates H2O2-induced apoptosis in rat H9C2 cardiomyocytes via targeting PTEN. Oncotarget, 2016, 7(10): 10870-8. DOI:10.18632/oncotarget.7678 |
| 53. | Singh SB, Lin HC. Hydrogen Sulfide in Physiology and Diseases of the Digestive Tract. Microorganisms, 2015, 3(4): 866-89. DOI:10.3390/microorganisms3040866 |
Figures(3) / Tables(1)
Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail:
info@rhhz.net 
| Nucleases | Genes | Modification | Components | Injected site | Application | Reference |
| ZFN | IGM | KO/KI | ZFN mRNA | Cytoplasm | Immunology | |
| APOCIII | KO | ZFN mRNA | Cytoplasm | Lipid metabolism and atherosclerosis | [85] | |
| APOE | KO | ZFN mRNA | Pronuclear | Lipid metabolism and atherosclerosis | [86] | |
| CETP | KO | ZFN mRNA | Cytoplasm | Lipid metabolism and atherosclerosis | [88] | |
| TALENs | RAG1 | KO | TALEN mRNA | Cytoplasm | Immunodeficiency | [36] |
| RAG2 | KO | |||||
| FAH | KO | TALEN mRNA | Cytoplasm | Hereditary tyrosinemia type 1 | [95] | |
| CRISPR/ Cas9 | FBN1 | KO | Cas9 mRNA, sgRNA | Cytoplasm | Marfanoid-progeroid- lipodystrophy syndrome | [96] |
| DMD | KO | Cas9 mRNA, sgRNA | Cytoplasm | Duchenne muscular dystrophy | [97] | |
| ANO5 | KO | Cas9 mRNA, sgRNA | Cytoplasm | Muscular dystrophy | [98] | |
| aA-Crystallin | KO | Cas9 mRNA, dual sgRNA | Cytoplasm | Congenital cataracts | [99] | |
| GJA8 | KO | Cas9 mRNA, dual sgRNA | Cytoplasm | Congenital cataracts | [100] | |
| APOE | KO | Cas9 mRNA, sgRNA | Cytoplasm | Lipid metabolism and atherosclerosis | [37] | |
| LDLR | KO | |||||
| CD36 | KO | |||||
| RYR2 | KO | Cas9 mRNA, sgRNA | Cytoplasm | Heart arrhythmia. | ||
| LDLR | KO | Cas9 mRNA, sgRNA | Cytoplasm | Lipid metabolism and atherosclerosis | [101] | |
| MSTN | KO | Cas9 mRNA, sgRNA | Cytoplasm | Muscle hypertrophy | [102-103] | |
| SRY | KO | Cas9 mRNA, sgRNA | Cytoplasm | Sex reversal syndromes and hermaphroditism syndromes | [104-105] | |
| PHEX | KO | Cas9 mRNA, dual sgRNA | Cytoplasm | X-linked hypophosphatemia | [106] | |
| LMNA | KO | Cas9 mRNA, sgRNA | Cytoplasm | Premature aging syndrome | [107] | |
| WRN | KO | Cpf1 mRNA, sgRNA | Cytoplasm | Werner syndrome | [108] | |
| TYR | KO | Circular plasmid | Pronuclear | Coat color | [109] | |
| TYR | KO | Cas9 mRNA, dual sgRNAs | Cytoplasm | Coat color | [110] | |
| ATP7B | Precision point mutation | Cas9 mRNA, 2sgRNA, ssODN | Cytoplasm | Wilson Disease | [111] | |
| TYR | Precision point mutation | Cas9 mRNA, sgRNA, ssODN | Cytoplasm | Coat color | [112] | |
| TYR | KO, large fragment deletion | Cas9 mRNA, dual sgRNAs | Cytoplasm | Coat color | [113] | |
| FOXN1 | Multiplex gene KO | Cas9 mRNA, sgRNA | Cytoplasm | Immunodeficiency | [114-115] | |
| PRKDC | ||||||
| RAG1 | Multiplex gene KO | Cas9 mRNA, sgRNA | Cytoplasm | Immunodeficiency | [114-116] | |
| RAG2 | ||||||
| IL2RG | ||||||
| TIKI1 | Multiplex gene KO | Cas9 mRNA, sgRNA | Cytoplasm | Head development | [28] | |
| ALB | Serum albumin | |||||
| FUT1 | Multiplex gene KO using a single sgRNA | Cas9 mRNA, sgRNA | Cytoplasm | Fucosyltransferases enzymes activity | [117] | |
| FUT2 | ||||||
| SEC1 | ||||||
| ROSA 26 | KI | Cas9 mRNA, sgRNA, dsDNA | Cytoplasm | Safe harbor gene | [118-119] | |
| APOA1 | Cytoplasm | Lipid metabolism and atherosclerosis | ||||
| Base editor | MSTN | Base editing | BE3 mRNA | Cytoplasm | Muscle hypertrophy | [41] |
| LMNA | Hutchinson−Gilford progeria syndrome | |||||
| TYR | Coat color | |||||
| DMD | Base editing | ABE7.10 mRNA | Cytoplasm | Duchenne muscular dystrophy | ||
| KO: knock-out; KI: knock-in. | ||||||
DownLoad:
CSV
Authors and Reviewers
